Ranking Antidepressants by Ease of Discontinuation
Fluoxetine is the easiest to discontinue, followed by mirtazapine, with amitriptyline being the most difficult to discontinue.
Ranking (Easiest to Most Difficult)
1. Fluoxetine (Easiest)
Fluoxetine has a uniquely long half-life (approximately 3-4 weeks when including its active metabolite norfluoxetine), which provides a built-in "self-tapering" effect that substantially reduces discontinuation syndrome risk 1. The guidelines specifically note that longer half-life SSRIs like fluoxetine require dose adjustments at approximately 3- to 4-week intervals, compared to 1- to 2-week intervals for shorter-acting agents 1. This pharmacokinetic property makes fluoxetine the most forgiving antidepressant when discontinuing treatment.
2. Mirtazapine (Intermediate)
Mirtazapine carries a moderate risk of discontinuation syndrome. The FDA label explicitly warns that discontinuation (particularly when abrupt) can cause dizziness, abnormal dreams, sensory disturbances (including paresthesia and electric shock sensations), agitation, anxiety, fatigue, confusion, headache, tremor, nausea, vomiting, and sweating 2. The FDA specifically recommends gradual dose reduction rather than abrupt cessation 2. However, mirtazapine is not among the antidepressants most strongly associated with discontinuation syndrome in the guideline literature.
3. Amitriptyline (Most Difficult)
Amitriptyline, as a tricyclic antidepressant (TCA), presents the greatest challenge for discontinuation. The guidelines explicitly state that "rapid dose decrease or abrupt discontinuance of benzodiazepines can produce withdrawal symptoms, including rebound insomnia, similar to that of barbiturates and alcohol" when discussing TCAs 3. TCAs require discontinuation over 10 to 14 days to limit withdrawal symptoms 4. The anticholinergic, cardiovascular, and sedative properties of amitriptyline compound the difficulty of discontinuation, as patients may experience rebound effects when these are suddenly removed.
Key Clinical Considerations
Discontinuation syndrome characteristics:
- The syndrome includes dizziness, fatigue, sensory disturbances, gastrointestinal symptoms, and flu-like symptoms 1
- Shorter-acting agents (like paroxetine, sertraline, fluvoxamine) are most problematic among SSRIs 1
- TCAs carry additional risks of anticholinergic rebound and cardiovascular effects 4
Practical tapering approach:
- Fluoxetine may often be stopped without tapering due to its long half-life, though gradual reduction is still preferred
- Mirtazapine requires gradual tapering per FDA guidance 2
- Amitriptyline mandates a 10-14 day taper minimum 4
Common pitfall: Assuming all antidepressants require the same discontinuation approach. The pharmacokinetic differences between these agents are substantial and directly impact discontinuation difficulty.